---
audienceLevel: patient
cancerTypes:
- general
citation: NCI, 2025
language: en
lastReviewed: '2025-12-30'
license: public_domain
reviewFrequency: quarterly
source: NCI
sourceType: 02_nci_core
status: active
tags:
- treatment
title: Selinexor - NCI
url: https://www.cancer.gov/about-cancer/treatment/drugs/selinexor
version: v1
---

# Selinexor - NCI

# Selinexor

Placeholder slot

(SEH-lih-NEK-sor)

This page contains brief information about selinexor
and a collection of links to more information about the use of
this drug, research results, and ongoing clinical trials.

US Brand Name(s)

Xpovio

FDA Approved

Yes

[FDA label information for this drug is available at DailyMed.](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f6dd2682-75a6-4863-90a8-a3197f6f78a8&audience=consumer)

## Use in Cancer

Selinexor
is approved to treat:

- **[Diffuse large B-cell lymphoma](/Common/PopUps/popDefinition.aspx?id=428286&version=Patient&language=English)** (certain types). It is used in adults whose disease has [relapsed](/Common/PopUps/popDefinition.aspx?id=45866&version=Patient&language=English) (come back) or is [refractory](/Common/PopUps/popDefinition.aspx?id=45863&version=Patient&language=English) (does not [respond](/Common/PopUps/popDefinition.aspx?id=44085&version=Patient&language=English) to treatment) and who have received at least two types of [systemic therapy](/Common/PopUps/popDefinition.aspx?id=45922&version=Patient&language=English).¹
- **[Multiple myeloma](/Common/PopUps/popDefinition.aspx?id=45793&version=Patient&language=English).** It is used:
- With bortezomib and [dexamethasone](/Common/PopUps/popDefinition.aspx?id=45262&version=Patient&language=English) in adults who have received at least one treatment.
- With dexamethasone in adults whose disease has relapsed or is refractory and who have received at least four treatments that included at least two [proteasome inhibitors](/Common/PopUps/popDefinition.aspx?id=393541&version=Patient&language=English), at least two [immunomodulating agents](/Common/PopUps/popDefinition.aspx?id=739791&version=Patient&language=English), and an anti-CD38 [monoclonal antibody](/Common/PopUps/popDefinition.aspx?id=46066&version=Patient&language=English).

¹This use is approved under FDA’s [Accelerated Approval Program](https://www.fda.gov/ForPatients/Approvals/Fast/ucm405447.htm). As a condition of approval, a [confirmatory trial(s)](/Common/PopUps/popDefinition.aspx?id=799146&version=Patient&language=English) must show that selinexor provides a clinical benefit in these patients.

Selinexor
is also being studied in the treatment of other types of
[cancer](/Common/PopUps/popDefinition.aspx?id=45333&version=Patient&language=English).

## More About Selinexor

[Definition from the NCI Drug Dictionary](https://www.cancer.gov/publications/dictionaries/cancer-drug/def/734824) - Detailed scientific definition and other names for this drug.

MedlinePlus Information on [Selinexor](https://medlineplus.gov/druginfo/meds/a619044.html) - A lay language summary of important information about this drug that may include the following:

- warnings about this drug,
- what this drug is used for and how it is used,
- what you should tell your doctor before using this drug,
- what you should know about this drug before using it,
- other drugs that may interact with this drug, and
- possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

## Research Results and Related Resources

[Targeted Cancer Therapies](https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies)

## Clinical Trials Accepting Patients

[Find Clinical Trials for Selinexor](https://www.cancer.gov/research/participate/clinical-trials/intervention/C102546) - Check for trials from NCI's list of cancer clinical trials now accepting patients.
